Zika virus (ZIKV) is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since spread to South Asia and recently to South America. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections. The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases. In April 2016, the Centers for Disease Control and Prevention in the USA, confirmed the link between ZIKV infection of the foetus with microcephaly (CDC).
Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms, ZIKV infected individuals can easily be misdiagnosed as a dengue infection and vice-versa. Currently, there is no vaccine or specific treatment available for ZIKV infection.
Analysis of ZIKV sequences from infected patients have shown that the strain circulating in South America in 2015 differs to the strain originally isolated in 1947 in Uganda (the “Uganda” strain). The South American strain was first isolated and sequenced from a patient in Suriname, and hence is known as the Zika Suriname strain (Enfissi, A) .
The Native Antigen Company supply a range of products to support researchers working with Zika virus proteins including NS1 proteins; Envelope protein and Zika virus VLP.
- Centers for Disease Control and Prevention. CDC Concludes Zika Causes Microcephaly and Other Birth Defects.
- Enfissi A. et al (2016). Zika virus genome from the Americas. Lancet 387(10015):227-8
We hold good stocks of all our antigens to ensure a rapid delivery service worldwide. We like to be in touch with our customers so please drop us a line or give us a call on +44 (0)1865 595230. To place an order, please email email@example.com and for further information including price inquiries, bulk preparations and contract services email: firstname.lastname@example.org.